|
⚲
|
| Keyboard |
| Lux Capital Management LLC
✚
|
|
|---|---|
| CRD # | 163026 |
| SEC # | 802-75425 |
| CIK # | 0001592843 |
| AUM | |
| Employees | |
| Phone | 646-475-4385 |
| Address | 920 Broadway New York, NY 10010 |
| Source | [IAPD] [EDGAR] [Website] [Twitter] |
| Total AUM ($) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| VC | Lux Defense Leaders LP | [2026-03-31] | 211.8 M | |
| Offered $200,000,000 · Filed 2025-03-31 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $200,000,000 · Duration One year or less · Revenue Decline to Disclose | ||||
| VC | Lux Ventures IX LP | [2026-03-31] | 1,575.8 M | |
| Offered $1,500,000,000 · Filed 2025-12-15 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $1,500,000,000 · Duration One year or less · Revenue Decline to Disclose | ||||
| VC | Pioneer Pier Investments LP | [2025-03-31] | 150.0 M | 434.0 M |
| Offered $150,000,000 · Filed 2024-02-16 (D) · Exemption 506(b), 3(c), 3(c)(7) · Duration One year or less · Revenue Decline to Disclose | ||||
| VC | Lux Ventures VIII Entrepreneurs Fund LP | [2024-03-28] | 3.9 M | 7.3 M |
| Offered $3,885,000 · Filed 2023-04-14 (D) · Exemption 506(b), 3(c), 3(c)(1) · Duration One year or less · Revenue Decline to Disclose | ||||
| VC | Lux Ventures VIII LP | [2024-03-28] | 1,141.7 M | 2,085.2 M |
| Offered $1,141,725,500 · Filed 2023-04-14 (D) · Exemption 506(b), 3(c), 3(c)(7) · Duration One year or less · Revenue Decline to Disclose | ||||
| VC | Lux Total Opportunities LP | [2023-03-28] | 1,109.5 M | |
| Offered $300,000,000 · Filed 2017-11-28 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $300,000,000 · Duration One year or less · Revenue Decline to Disclose | ||||
| VC | Lux Ventures VII Entrepreneurs Fund LP | [2022-03-23] | 498.0 M | 17.6 M |
| Offered $498,000,000 · Filed 2019-08-12 (D) · Exemption 506(b), 3(c), 3(c)(7) · Duration One year or less · Revenue Decline to Disclose | ||||
| VC | Lux Ventures VII LP | [2022-03-23] | 498.0 M | 1,329.5 M |
| Offered $498,000,000 · Filed 2019-08-12 (D) · Exemption 506(b), 3(c), 3(c)(7) · Duration One year or less · Revenue Decline to Disclose | ||||
| VC | Lux Co-Invest Opportunities II LP | [2020-03-17] | 1,250.6 M | |
| Offered $300,000,000 · Filed 2017-11-28 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $300,000,000 · Duration One year or less · Revenue Decline to Disclose | ||||
| VC | Lux Ventures VI LP | [2020-03-17] | 498.0 M | 1,364.4 M |
| Offered $498,000,000 · Filed 2019-08-12 (D) · Exemption 506(b), 3(c), 3(c)(7) · Duration One year or less · Revenue Decline to Disclose | ||||
| View All | ||||
| AUM Breakdown | Accounts | AUM ($) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 0 | 0.0 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 0 | 0.0 |
| By Discretionary | ||
| Discretionary | 0 | 0.0 |
| Non-Discretionary | 0 | 0.0 |
| Total | 0 | 0.0 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.0 | |
| United States Persons | 0.0 | |
| Total | 0 | 0.0 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Peter Hebert | Director, Executive Officer | 44 | 2 | |
| Josh Wolfe | Director, Executive Officer | 39 | 2 | |
| Robert Paull | Director, Executive Officer | 22 | 2 | |
| Lux Venture Partners IX LLC | Director | 2 | 2 | |
| Lux Venture Partners VIII LLC | Director | 2 | 1 | |
| Lux Venture Partners VI LLC | Director | 2 | 1 | |
| Peter Hbert | Executive Officer | 2 | 1 | |
| Lux Venture Partners III LLC | Promoter | 2 | 1 | |
| Lux Venture Partners V LLC | Promoter | 1 | 1 | |
| Lux Ventures Cayman III General Partner Limited | Promoter | 1 | 1 | |
| Lux Venture Partners IV LLC | Promoter | 1 | 1 | |
| Lux Defense Leaders GP LLC | Director | 1 | 1 | |
| Lux Venture Partners Cayman III LP | Promoter | 1 | 1 | |
| Pioneer Pier Investments GP LLC | Director | 1 | 1 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 3 | [0001592843] | |
| 4 | [0001592843] | |
| SC 13D | [0001592843] | |
| SC 13G | [0001592843] |
| Form 13D/13G Filer | Form 13D/13G Subject | Filed |
|---|---|---|
| Lux Capital Management LLC | Recursion Pharmaceuticals Inc | [2022-02-14] |
| Lux Capital Management LLC | Science 37 Holdings Inc | [2021-10-18] |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Science 37 Holdings Inc SNCE
Common Stock
|
2022-04-04 | Other | 2,914,667 | $0.00 | |
|
Everspin Technologies Inc MRAM
Series A Preferred Stock · derivative
|
2016-10-13 | Conversion | 219,916 | $0.00 | |
|
Everspin Technologies Inc MRAM
Common Stock
|
2016-10-13 | Conversion | 219,916 | ||
|
Everspin Technologies Inc MRAM
Common Stock
|
2016-10-13 | Conversion | 131,719 | $6.40 | 843,002 |
|
Everspin Technologies Inc MRAM
Common Stock
|
2016-10-13 | Conversion | 89,946 | $6.40 | 575,654 |
|
Everspin Technologies Inc MRAM
Common Stock
|
2016-10-13 | Buy | 137,420 | $8.00 | 1,099,360 |
|
Everspin Technologies Inc MRAM
Common Stock
|
2016-10-13 | Conversion | 118,606 | ||
|
Everspin Technologies Inc MRAM
5% Convertible Subordinated Promissory Note · derivative
|
2016-10-13 | Conversion | $0.00 | ||
|
Everspin Technologies Inc MRAM
5% Convertible Subordinated Promissory Note · derivative
|
2016-10-13 | Conversion | $0.00 | ||
|
Everspin Technologies Inc MRAM
Series B Preferred Stock · derivative
|
2016-10-13 | Conversion | 118,606 | $0.00 | |
|
Dare Bioscience Inc CERU
Series B Convertible Preferred Stock · derivative
|
2014-04-15 | Conversion | 706,026 | $0.00 | |
|
Dare Bioscience Inc CERU
Common Stock
|
2014-04-15 | Conversion | 131,713 | ||
|
Dare Bioscience Inc CERU
Common Stock
|
2014-04-15 | Conversion | 142,122 | ||
|
Dare Bioscience Inc CERU
Common Stock
|
2014-04-15 | Conversion | 79,780 | ||
|
Dare Bioscience Inc CERU
Common Stock
|
2014-04-15 | Buy | 106,224 | $7.00 | 743,568 |
|
Dare Bioscience Inc CERU
Common Stock
|
2014-04-15 | Conversion | 98,835 | ||
|
Dare Bioscience Inc CERU
Common Stock
|
2014-04-15 | Conversion | 37,378 | ||
|
Dare Bioscience Inc CERU
Common Stock
|
2014-04-15 | Conversion | 171,525 | ||
|
Dare Bioscience Inc CERU
Common Stock
|
2014-04-15 | Conversion | 184,422 | ||
|
Dare Bioscience Inc CERU
7% Convertible Promissory Notes · derivative
|
2014-04-15 | Conversion | $0.00 | ||
| showing 20 of 37 most recent transactions | |||||